Navigation Links
Pharmasset Announces Further Expansion of ELECTRON Trial in Hepatitis C
Date:10/10/2011

ment naive patients with HCV genotype 1 (GT1) in the US.

About ELECTRON

ELECTRON is an exploratory study of PSI-7977 for the treatment of chronic HCV infection. Part 1 of the trial is evaluating 12-week regimens of interferon-free PSI-7977 400mg QD with ribavirin (RBV), and three abbreviated duration peginterferon (Peg-IFN) regimens of 4, 8, or 12 weeks in treatment-naive patients with HCV GT2 or GT3. The primary endpoint of the trial is the safety and tolerability of PSI-7977 400mg QD and RBV for 12 weeks, administered with or without Peg-IFN. On May 11, 2011, Pharmasset announced the completed enrollment of Part 1 of ELECTRON:

  • PSI-7977 400 mg with Peg-IFN and RBV for 12 weeks (GT2/3)
  • PSI-7977 400 mg with RBV for 12 weeks, Peg-IFN weeks 1-8 only (GT2/3)
  • PSI-7977 400 mg with RBV for 12 weeks; Peg-IFN weeks 1-4 only (GT2/3)
  • PSI-7977 400 mg with RBV for 12 weeks (GT2/3)

In Part 2 of ELECTRON, a 5th cohort was added to explore PSI-7977 monotherapy in treatment naive patients with HCV GT2 or GT3:

  • PSI-7977 400 mg monotherapy for 12 weeks (n=10 GT2/3)

Following on the previously reported 100% SVR12 in treatment-naive subjects with HCV GT2/3 (PROTON), a 6th cohort was added to ELECTRON to explore an 8-week duration of PSI-7977Peg-IFN/RBV.  The previously announced 7th cohort in HCV GT1 patients with a prior "null" response to Peg-IFN, has been modified to an interferon-free 12-week regimen of PSI-7977/RBV.

  • PSI-7977 400 mg with Peg-IFN/RBV for 8 weeks (n=10 GT2/3 treatment-naive)
  • PSI-7977 400 mg with RBV for 12 weeks (n=10 GT1 null)

In Part 3 of ELECTRON, two additional IFN-free regimens will be explored in treatment-naive patients with HCV GT1 and in treatment-experienced patients with HCV GT2 or GT3.  

    '/>"/>

SOURCE Pharmasset, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Pharmasset to Present at Two Upcoming Conferences
2. Pharmasset Initiates QUANTUM, a Phase 2b Interferon-Free Trial of PSI-7977 and PSI-938 for All HCV Genotypes
3. Pharmasset Announces Two-for-One Forward Stock Split
4. Pharmasset to Present at Canaccord Genuity Growth Conference
5. Pharmasset Reports Fiscal Third Quarter 2011 Financial Results
6. Pharmasset Announces the Expansion of the ELECTRON Trial in Chronic Hepatitis C
7. Pharmasset to Present at Two Upcoming Investor Conferences
8. Pharmasset Reports Fiscal Second Quarter 2011 Financial Results
9. Pharmasset Initiates Phase 2b ATOMIC Trial of PSI-7977 for Multiple HCV Genotypes
10. Pharmasset to Webcast an Investor Event From the EASL Meeting
11. Pharmasset to Present at Three Upcoming Investor Conferences
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2014)... York , July 29, 2014 ... Transparency Market Research "Orthopedic Trauma Fixation Devices Market - ... 2014 - 2020", the global orthopedic trauma fixation devices ... and is expected to grow at a CAGR of ... value of USD 9.3 billion in 2020. ...
(Date:7/29/2014)... BEDFORD, Mass. , July 29, 2014  Instrumentation Laboratory ... identity, including a new corporate logo. This is part of ... IL. Founded in Boston, MA ... Group family of companies since 1992.  Other companies in the ... ), Biokit and Systelab ( Barcelona, Spain ).  ...
(Date:7/29/2014)... , July 29, 2014 Research ... "Global Respiratory Devices Market 2014-2018" report to ... A respiratory device is a medical device ... is having difficulty in breathing and cannot achieve adequate ... such as cystic fibrosis, asthma, COPD, and ARDS require ...
Breaking Medicine Technology:Orthopedic Trauma Fixation Devices Market is Expected to Reach USD 9.3 Billion Globally in 2020: Transparency Market Research 2Orthopedic Trauma Fixation Devices Market is Expected to Reach USD 9.3 Billion Globally in 2020: Transparency Market Research 3Orthopedic Trauma Fixation Devices Market is Expected to Reach USD 9.3 Billion Globally in 2020: Transparency Market Research 4Instrumentation Laboratory Unveils New Corporate Brand 2Instrumentation Laboratory Unveils New Corporate Brand 3Global Respiratory Devices Market 2014-2018 2
... Pharmaceutical Inc. (Nasdaq: BMRN ) today hosted ... company,s management team and industry experts provided an update ... and development pipeline. "We believe 2011 has ... late stage and early stage clinical development programs," said ...
... Africa, Dec. 8, 2011   Leatt Corporation (OTC: LEAT.PK), ... brace system designed to help prevent potentially devastating injuries to ... its Leatt-Brace GPX Pro neck brace has been named one ... Motocross magazine. Transworld Motocross notes ...
Cached Medicine Technology:Highlights from BioMarin's Research & Development Day 2Highlights from BioMarin's Research & Development Day 3Highlights from BioMarin's Research & Development Day 4Highlights from BioMarin's Research & Development Day 5Highlights from BioMarin's Research & Development Day 6Leatt-Brace GPX Pro Named a 2011 Product of the Year By Transworld Motocross Magazine 2
(Date:7/29/2014)... Hopkins researchers say they have discovered a chemical alteration ... that, if confirmed in larger studies, could give doctors ... risk of attempting suicide. , The discovery, described online ... that changes in a gene involved in the function ... significant role in turning what might otherwise be an ...
(Date:7/29/2014)... Daily Gossip reveals in its Nasal Polyps Treatment Miracle review ... his condition with the use of this method too. In ... , He claimed that he was able to cure ... Since his method turned out being so effective, he decided ... , The Nasal Polyps Treatment Miracle program was created ...
(Date:7/29/2014)... Colorado (PRWEB) July 29, 2014 Daily Gossip ... was created by a holistic nutritional and functional medicine practitioner, ... of overcoming this problem. , Karen suffered from leaky gut, ... much time to develop this unique treatment. , Karen ... method, with sufferers from all around the world. The author ...
(Date:7/29/2014)... 2014 Parker Waichman LLP, a national ... injured by defective drugs and medical devices, reports that ... in Canada who allege that they were never warned ... the low testosterone injection Delatestryl (Court File No. 3704CP/14). ... the Ontario Superior Court of Justice. , “Testosterone lawsuits ...
(Date:7/29/2014)... July 29, 2014 Daily Gossip reveals in ... step holistic system that will permanently eliminate all the symptoms ... his natural treatment will banish symptoms such as mild hearing ... sound heard by patients will be gone forever. , The ... days. The author of this program says that at the ...
Breaking Medicine News(10 mins):Health News:A blood test for suicide? 2Health News:A blood test for suicide? 3Health News:Nasal Polyps Treatment Miracle Review Reveals How to Cure Nasal Polyps Without Surgery 2Health News:Leaky Gut Cure Review Reveals Karen Brimeyer’s Natural Way to Heal Leaky Gut 2Health News:Class Action Lawsuit in Canada Alleges Manufacturer of Delatestryl Testosterone Injection Failed to Warn of Cardiovascular Risks, Parker Waichman LLP Reports 2Health News:Class Action Lawsuit in Canada Alleges Manufacturer of Delatestryl Testosterone Injection Failed to Warn of Cardiovascular Risks, Parker Waichman LLP Reports 3Health News:Tinnitus Miracle Review Exposes the Only Holistic System for Tinnitus Cure 2
... hospitals and health care clinics in China have been ... be prepared to handle cases. //The Ministry of Health ... unusual rise in diarrhea cases. ,As Norovirus ... caution while eating in restaurants and hotels. These viruses ...
... sketched out an action plan to bring down the HIV ... will be allotted to implement a series of programmes towards ... this campaign, the Aboriginal and Torres Strait Islander community would ... practitioners, information related to HIV prevention also will be circulated. ...
... health of Cuban leader Fidel Castro has deteriorated following ... Pais reported Tuesday.// ,Castro is in 'very grave' ... intestinal infection, El Pais said citing sources from the ... Sabrido. ,Sabrido, chief surgeon at the Gregorio ...
... the benefits of tomato and broccoli in the management of ... vegetables, are a great blessing in the reduction of tumors,// ... ,It is estimated that one out of four ... the most notorious of male cancers. Annually, 32,000 cases are ...
... have found that a score that measures the proteomic ... // ,Researchers from Yale University, led by Catalin ... markers that were closely associated with inflammation in the ... proteins?€the "Mass Restricted" (MR) score. This score has been ...
... - there is no proof for growth hormone therapy’s anti-aging ... University, after analyzing 31 scientific papers based on growth hormone.// ... suggest that giving growth hormone to an otherwise healthy person ... however, that there was substantial potential for adverse side effects.' ...
Cached Medicine News:Health News:Tomato and Broccoli Combo may Help Fight Prostate Cancer 2Health News:Is Growth Hormone – a Key to Longevity 2
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
Medicine Products: